CTRI/2022/10/046795尚未招募未知
Study on antidyslipidemic and insulin sensitising effects of saroglitazar in patients with diabetic dyslipidemia
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Patients with diabetic dyslipidemia with fasting triglycerides > 200-400 who are being treated with any of non insulin secretogogues( alpha glucose daze inhibitors, biguanides, SGLT-2 inhibitors) and low dose statin for at least 3 months.
排除标准
- •patients on insulin, glitazar, glitazone, insulin secretogagues (sulfonylureas)
- •history of Thyroid disease, cardiac illness, liver disease (s.bilirubin > 2 times Upper normal limits), renal dysfunction(s.creatinine > 1.2mg/dL)
- •comorbid serious illness like tuberculosis, malignancy, HIV.
- •Pregnant and nursing mother
研究者
相似试验
已完成
不适用
Investigation for the effect of anti-dyslipidemic drugs on serum level of trans-fatty acidsdyslipidemiaJPRN-UMIN000026984Kobe University Graduate School of Medicine40
已完成
3 期
?Anti-diabetic effects of Dorema aucheriPatients with Type II Diabetes.Non-insulin-dependent diabetes mellitusIRCT2014123120502N1Shahid Sadoughi University of Medical Sciences150
招募中
Unknown
A Clinical study in patients with dyslipidemia to determine the actual status of the percentage of patients achieving the target values for the management of LDL-Cholesterol specified in the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases (2022 edition)DyslipidemiaJPRN-UMIN000051501TOKYO CENTER CLINIC180
已完成
不适用
A Clinical study in patients with dyslipidemia to determine the status of recognition and the percentage of patients achieving the target values for the management of each lipid parameter specified in the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases (2022 edition), and to follow-up the achievement of the target values by subsequent treatment approaches.DyslipidemiaJPRN-UMIN000046687Medical Corporation Chiseikai Tokyo Center Clinic350
已完成
不适用
Clinical study to investigate lipid-modifying effects of a Saskatoon berry extract - a randomized, double-blind, placebo-controlled parallel studyHealthy subjectsDRKS00015503Prairie Berries Europe GmbH50